Evidence map›Paper›PMID 18637185›Full record

ArticleNutrition & metabolism2008

Potential antiproteolytic effects of L-leucine: observations of in vitro and in vivo studies.

Nelo E Zanchi, Humberto Nicastro, Antonio H Lancha

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Nutrition & metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01192009 nacompletednot on this mapstarted 2011, after this paper: background citation

Leucine and Skeletal Muscle Disuse: Clinical Anti-Atrophic Effectiveness and Related Mechanisms

TypeinterventionalSponsorUniversity of Sao PauloRan2011 to 2013Enrolled22ConditionsDisuse AtrophyArmsLeucine, Placebo
NCT02773771 phase2 / phase3withdrawnnot on this mapstarted 2017, after this paper: background citation

Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit (STROMA-ICU)

TypeinterventionalSponsorMassachusetts General HospitalRan2017 to 2019Enrolled0ConditionsMuscle AtrophyArmsbeta-hydroxy-beta-methylbutyrate, Placebo, Vital HP®
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nelo E ZanchiLaboratory of Applied Nutrition and Metabolism, Physical Education and School of Sports, University of São Paulo, São Paulo, Brazil. neloz@ig.com.br.
Humberto Nicastro
Antonio H Lancha
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of present review is to describe the effect of leucine supplementation on skeletal muscle proteolysis suppression in both in vivo and in vitro studies. Most studies, using in vitro methodology, incubated skeletal muscles with leucine with different doses and the results suggests that there is a dose-dependent effect. The same responses can be observed in in vivo studies. Importantly, the leucine effects on skeletal muscle protein synthesis are not always connected to the inhibition of skeletal muscle proteolysis. As a matter of fact, high doses of leucine incubation can promote suppression of muscle proteolysis without additional effects on protein synthesis, and low leucine doses improve skeletal muscle protein ynthesis but have no effect on skeletal muscle proteolysis. These research findings may have an important clinical relevancy, because muscle loss in atrophic states would be reversed by specific leucine supplementation doses. Additionally, it has been clearly demonstrated that leucine administration suppresses skeletal muscle proteolysis in various catabolic states. Thus, if protein metabolism changes during different atrophic conditions, it is not surprising that the leucine dose-effect relationship must also change, according to atrophy or pathological state and catabolism magnitude. In conclusion, leucine has a potential role on attenuate skeletal muscle proteolysis. Future studies will help to sharpen the leucine efficacy on skeletal muscle protein degradation during several atrophic states.

Identifiers

PMID18637185
PMCPMC2488337
OpenAlexW2001949790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.